Abstract:To examine the relationship between opioid and HIV‐1‐induced alterations in striatal monoamine concentrations and behavior, morphine was administered to HIV‐1 Tat transgenic mice for 2 weeks or 2 months. Morphine and Tat interacted to alter levels of dopamine, dopamine metabolites, norepinephrine, and 5‐hydroxyindoleacetic acid depending on the duration of exposure and neurotransmitter/metabolite assayed. Co‐exposure to Tat and morphine disrupted locomotor activity in a time‐dependent manner. Alternatively, Tat alone inhibited social exploratory behavior, whereas morphine alone tended to increase novelty‐seeking behavior. The data suggest that Tat and morphine effects on monoamine neurochemistry are complex and contribute to motor and exploratory behavioral dysregulation. Despite the advent of combination anti‐retroviral therapy (cART), nearly half of people infected with HIV treated with cART still exhibit HIV‐associated neurocognitive disorders (HAND). HAND can be worsened by co‐morbid opioid use disorder. The basal ganglia are particularly vulnerable to HIV‐1 and exhibit higher viral loads and more severe pathology, which can be exacerbated by co‐exposure to opioids. Evidence suggests that dopaminergic neurotransmission is disrupted by HIV exposure, however, little is known about whether co‐exposure to opioids may alter neurotransmitter levels in the striatum and if this in turn influences behavior. Therefore, we assayed motor, anxiety‐like, novelty‐seeking, exploratory, and social behaviors, and levels of monoamines and their metabolites following 2 weeks and 2 months of Tat and/or morphine exposure in transgenic mice. Morphine decreased dopamine levels, but significantly elevated norepinephrine, the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and the serotonin metabolite 5‐hydroxyindoleacetic acid, which typically correlated with increased locomotor behavior. The combination of Tat and morphine altered dopamine, DOPAC, and HVA concentrations differently depending on the neurotransmitter/metabolite and duration of exposure but did not affect the numbers of tyrosine hydroxylase‐positive neurons in the mesencephalon. Tat exposure increased the latency to interact with novel conspecifics, but not other novel objects, suggesting the viral protein inhibits exploratory behavior initiation in a context‐dependent manner. By contrast, and consistent with prior findings that opioid misuse can increase novelty‐seeking behavior, morphine exposure increased the time spent exploring a novel environment. Finally, Tat and morphine interacted to affect locomotor activity in a time‐dependent manner, while grip strength and rotarod performance were unaffected. Together, our results provide novel insight into the unique effects of HIV‐1 Tat and morphine on monoamine neurochemistry that may underlie their divergent effects on motor and exploratory behavior.

SRI-32743, a Novel Allosteric Modulator, Attenuates HIV-1 Tat Protein-Induced Inhibition of the Dopamine Transporter and Alleviates the Potentiation of Cocaine Reward in HIV-1 Tat Transgenic Mice

Effects of SRI-32743, a Novel Quinazoline Structure-Based Compound, on HIV-1 Tat and Cocaine Interaction with Norepinephrine Transporter

Identification of Pyrimidine Structure-Based Compounds As Allosteric Ligands of the Dopamine Transporter As Therapeutic Agents for NeuroHIV.

Impact of HIV-1 tat protein on methamphetamine-induced inhibition of vesicular monoamine transporter2-mediated dopamine transport and methamphetamine conditioned place preference in HIV-1 tat transgenic mice

Positive allosteric modulators of the serotonin 2C receptor as novel therapeutics for cocaine use disorder

HIV-1 Tat and cocaine impact astrocytic energy reservoirs and epigenetic regulation by influencing the LINC01133-hsa-miR-4726-5p-NDUFA9 axis

Analysis of Sigma-1 Receptor Antagonist BD1047 Effect on Upregulating Proteins in HIV-1-Infected Macrophages Exposed to Cocaine Using Quantitative Proteomics

Cannabinoid receptor 1 positive allosteric modulator ZCZ011 shows differential effects on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice

Suppression of HIV-TAT and cocaine-induced neurotoxicity and inflammation by cell penetrable itaconate esters

Inhibitory Neurotransmission Is Sex-Dependently Affected by Tat Expression in Transgenic Mice and Suppressed by the Fatty Acid Amide Hydrolase Enzyme Inhibitor PF3845 via Cannabinoid Type-1 Receptor Mechanisms

Protein Kinase D1-Dependent Phosphorylation of Dopamine D1 Receptor Regulates Cocaine-Induced Behavioral Responses

Rodent Models of HAND and Drug Abuse: Exogenous Administration of Viral Protein(s) and Cocaine

HIV Transactivator of Transcription Enhances Methamphetamine-Induced Parkinson's-like Behavior in the Rats.

HIV‐1 Tat and morphine interactions dynamically shift striatal monoamine levels and exploratory behaviors over time

Effects of acute Δ 9 -tetrahydrocannabinol on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice

HIV-1 Tat and Methamphetamine Co-Induced Oxidative Cellular Injury is Mitigated by N-acetylcysteine Amide (NACA) Through Rectifying Mtor Signaling.

Chemogenetic Activation of Medial Prefrontal Cortex Projections to the Nucleus Accumbens Shell Suppresses Cocaine-Primed Reinstatement in EcoHIV Infected Mice

Nicotinamide phosphoribosyltransferase regulates cocaine reward through Sirtuin 1

Astrocytic Regulation of Cocaine Locomotor Sensitization in EcoHIV Infected Mice

Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder